Trial Profile
A multi-center, randomized, double-blind, parallel group, placebo controlled, study in patients with non-chronic migraine to assess the efficacy, safety and tolerability of BID oral doses of BGG492 in migraine prevention
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Sep 2019
Price :
$35
*
At a glance
- Drugs Selurampanel (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 29 Sep 2014 Planned End Date changed from 1 Jun 2014 to 1 Nov 2016 as reported by ClinicalTrials.gov.
- 29 Sep 2014 Planned primary completion date changed from 1 Jun 2014 to 1 Nov 2016 as reported by ClinicalTrials.gov.
- 29 Sep 2014 Planned initiation date changed from 1 Jun 2013 to 1 May 2016 as reported by ClinicalTrials.gov.